BLAINJECTIONINJECTABLE
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
LYUMJEV (insulin lispro-aabc) by Eli Lilly and Company. Approved for insulin analog [epc]. First approved in 2020.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYUMJEV (insulin lispro-aabc) is a rapid-acting insulin analog approved by the FDA in June 2020 for use in insulin pump therapy and subcutaneous injection in patients with diabetes mellitus. It is formulated with excipients that accelerate absorption compared to standard insulin lispro, enabling faster postprandial glucose control. This product represents Eli Lilly's innovation in the competitive rapid-acting insulin market.
$15MPart D
PeakProduct is in peak commercial phase with moderate Part D claims volume, indicating stable market presence but with room for expansion in pump and injection segments.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
Started Aug 2022
183 enrolled
Type 1 Diabetes
Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®
Started May 2022
244 enrolled
Type 1 Diabetes
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
Started Feb 2022
25 enrolled
Diabetes Mellitus, Type 1
A Study of 2 Different Formulations of Insulin Lispro in Healthy Participants
Started May 2014
38 enrolled
Healthy Volunteers
A Study on the Effect of 2 Pen Devices on HbA1c
Started Oct 2009
263 enrolled
Diabetes Mellitus, Type 1
Worked on LYUMJEV at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.